Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.58 |
| ▸ | RAB9A | P51151 | 13/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.58 |
| ▸ | MAPT | P10636 | 10/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17626909 | 0.93 | ALDH1A1 (0.61) | NPC1RAB9AKDM4EMAPTPKM | |
| SCHEMBL17626914 | 0.84 | NPC1 (0.46) | NPC1RAB9AKDM4EMAPTPKM | |
| SCHEMBL16212738 | 0.81 | NPC1 (0.64) | NPC1RAB9AKDM4EMAPTPKM | |
| SCHEMBL17626767 | 0.80 | ALDH1A1 (0.55) | NPC1RAB9AKDM4EMAPTPKM | |
| SCHEMBL17626816 | 0.77 | RAB9A (0.57) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL17626879 | 0.76 | APP (0.58) | NPC1RAB9AKDM4EALDH1A1KMT2A | |
| SCHEMBL23407686 | 0.76 | ALDH1A1 (0.85) | NPC1RAB9AKDM4EMAPTPKM | |
| SCHEMBL17626857 | 0.76 | AHR (0.44) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL17626742 | 0.76 | TLR9 (0.47) | NPC1RAB9AKDM4EMAPTPKM | |
| SCHEMBL17626867 | 0.74 | TLR9 (0.58) | NPC1RAB9AKDM4EMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170128598-A1 | 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2017-05-11 | — | — | US | claimed |
| EP-2999701-A1 | 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | Hoffmann-La Roche Inc. (US) | 2016-03-30 | — | — | EP | claimed |
| US-9801961-B2 | 2-phenylimidazo[1,2-a]pyrimidines as imaging agents | HOFFMANN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9801961-B2 | 2-phenylimidazo[1,2-a]pyrimidines as imaging agents | HOFFMANN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9801961-B2 | 2-phenylimidazo[1,2-a]pyrimidines as imaging agents | HOFFMANN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170128598-A1 | 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170128598-A1 | 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170128598-A1 | 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2017-05-11 | — | — | US | disclosed |
| EP-2999701-B1 | 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | HOFFMANN LA ROCHE (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2999701-B1 | 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | HOFFMANN LA ROCHE (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2999701-A1 | 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | Hoffmann-La Roche Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128598-A1 | 2-PHENYLIMIDAZO[1,2-A]PYRIMIDINES AS IMAGING AGENTS | MAPT, AOC2, AOC3 | NPC1 1400/4885RAB9A 3502/4885KDM4E 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.